Tatva Chintan Pharma Chem Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹217 Cr +75% YoYSee revenue, profit and what management said. You are viewing Q3 FY26.
TC

Tatva Chintan Pharma Chem Ltd

Q3 FY26Chemicals & Petrochemicals

Tatva Chintan Pharma Chem Q3 FY26 earnings call: Revenue & Margins

Q3 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹131Cr
+52.3% YoY
+5.6% QoQ
Net profit
₹15Cr
Q3 FY25: ₹0 Cr
+50% QoQ
Margin
19%
+11 pp YoY
+1 pp QoQ

Tatva Chintan Pharma Chem Ltd Q3 FY26 key numbers

Revenue
Existing Dahej plant revenue expected to reach INR 850-900 crores, covering PASC, SDA, electrolyte, and PTC products.

As stated in Tatva Chintan Pharma Chem Ltd's Q3 FY26 earnings call transcript · published 8 Aug 2026. Reported figures, not investment advice.

Price₹1,616
Market cap₹4.0K Cr
P/E76.8

The short version

Existing Dahej plant revenue expected to reach INR 850-900 crores, covering PASC, SDA, electrolyte, and PTC products. Revenue growth of 20% to 30% year-on-year expected for FY '26 and similar growth anticipated for FY '27, bolstered by the commissioning of the new Jolva plant around Sep/Oct 2027 which will add new products and expand existing ones.

From Tatva Chintan Pharma Chem Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Existing Dahej plant revenue expected to reach INR 850-900 crores, covering PASC, SDA, electrolyte, and PTC products.
  • New Jolva plant targeting new agro products and expansion, contributing significantly from late 2027.
  • Pharma & Agro new intermediates (3 each) expected to contribute INR 200-250 crores additional revenue in calendar year 2027, ramping up from current sales base.
  • SDA segment projected to grow 25-30% in 2026 with capacity utilization around 55%, driven by Euro 7 norm demand surge starting 2027.
  • Semiconductor chemicals expected to reach full commercialization around 2028 with very large volume potential.

2 more points from Tatva Chintan Pharma Chem Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Tatva Chintan Pharma Chem Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • New plant at Jolva: Greenfield project with planned capex of INR 250-275 crores, expected execution within 18 months starting Q1 2026; aimed at commercializing new agro intermediate products and expanding existing ones.
  • Dahej plant: Recent capex of ~INR 100 crores focused mostly on utilization expansion, optimization, and operational excellence rather than capacity increase.
  • Jolva plant expected commissioning: Around September-October 2027, adding new products and revenue streams.

2 more points from Tatva Chintan Pharma Chem Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Chemicals & Petrochemicals

Ranked on what management guided this quarter

Guidance-ranked
2Shiv Texchem
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Tatva Chintan Pharma Chem Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • Tatva Chintan has onboarded two customers for the Structured Directing Agents (SDA) segment; one is in final contract signing and expected to start commercial supplies around August 2026.
  • The second customer's negotiations are ongoing, with commercialization anticipated in the second half of the current calendar year.
  • The Semiconductor Chemicals segment is in early stages; the company will execute its first plant trial order in the current quarter, with gradual full commercialization expected.
  • The new Jolva plant, targeted for commissioning around September-October 2027, is expected to support new agro products and expanded existing product lines.

2 more points from Tatva Chintan Pharma Chem Ltd's call on order book

Create a free account to keep reading this call

Tatva Chintan Pharma Chem Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Tatva Chintan Pharma Chem Ltd Q3 FY26 results — key figures

Tatva Chintan Pharma Chem Ltd Q3 FY26 reported results vs Q3 FY25, ₹ crore
₹ CrQ3 FY26Q3 FY25YoYQ2 FY26QoQ
Revenue13186+52.3%124+5.6%
Operating profit (EBITDA)257+257.1%22+13.6%
Operating margin19%8%+11 pp18%+1 pp
Profit before tax18-0—14+28.6%
Net profit (PAT)150—10+50%
EPS (₹)6.490.06+10716.7%4.24+53.1%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹217 Cr, net profit ₹21 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Chemicals & Petrochemicals this season

  • Neochem Bio (Q3 FY26)

    Revenue for Q2 FY26 (Sept’25) stood at ₹4,583.16 Lakh. Key investor presentation takeaways from Neochem Bio Solutions Ltd's Q3 FY26 investor presentation — and

  • Thirumalai Chemicals (Q3 FY26)

    Q3 FY26 Revenue from Operations (INR Cr):** . Key investor presentation takeaways from Thirumalai Chemicals Ltd's Q3 FY26 investor presentation — and how it ran

  • IVP (Q3 FY26)

    Q3 FY26 Revenue from Operations: ₹144.97 crore . Key investor presentation takeaways from IVP's Q3 FY26 investor presentation — and how it ranks against sector

  • Gujarat Alkalies (Q3 FY26)

    3,144.48 Crores, down from Rs. Key investor presentation takeaways from Gujarat Alkalies & Chemicals Ltd's Q3 FY26 investor presentation — and how it ranks agai

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Tatva Chintan Pharma Chem Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Tatva Chintan Pharma Chem Ltd Q3 FY26 results?

Existing Dahej plant revenue expected to reach INR 850-900 crores, covering PASC, SDA, electrolyte, and PTC products. Revenue growth of 20% to 30% year-on-year expected for FY '26 and similar growth anticipated for FY '27, bolstered by the commissioning of the new Jolva plant around Sep/Oct 2027 which will add new products and expand existing ones.

What is Tatva Chintan Pharma Chem Ltd share price analysis?

Tatva Chintan Pharma Chem Ltd currently shows a neutral. The stock trades at a P/E of 76.8 with a market cap of ₹4,025 Cr. Investors should review the full earnings analysis for detailed insights.

Is Tatva Chintan Pharma Chem Ltd planning capital expenditure?

New plant at Jolva: Greenfield project with planned capex of INR 250-275 crores, expected execution within 18 months starting Q1 2026; aimed at commercializing new agro intermediate products and expanding existing ones.

Keep Tatva Chintan Pharma Chem Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.